nach oben

European Journal of Nuclear Medicine and Molecular Imaging

Erschienen in:

14.06.2022 | Editorial

EANM-EAU consensus on PSMA PET/CT in respect to radioligand therapy ([¹⁷⁷Lu]Lu-PSMA)

verfasst von: Stefano Fanti, Jolanta Kunikowska, Jochen Walz, Wim Witjes, Anders Bjartell

Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging | Ausgabe 10/2022

Einloggen, um Zugang zu erhalten

Excerpt

A paper regarding consensus statements on the role of prostate-specific membrane antigen (PSMA) PET/CT (e.g. [⁶⁸Ga]Ga-PSMA-11, [¹⁸F]PSMA-1007, [¹⁸F]DCFPyL, herein and further referred to as “PSMA PET/CT”) in patients with prostate cancer and in respect to radioligand therapy ([¹⁷⁷Lu]Lu-PSMA) has recently been published in Eur Urol Oncol [1], resulting from a collaboration between European Association of Nuclear Medicine (EANM) and European Association of Urology (EAU). It is well known that PSMA PET/CT is increasingly used for men with prostate cancer (PCa) in various clinical settings, and now incorporated in several international guidelines [2]; furthermore, procedural guidelines for performing PSMA PET/CT have been published [3]. …

Fanti S, Briganti A, Emmett L, et al. EAU-EANM consensus statements on the role of PSMA PET/CT in patients with prostate cancer and in respect to radioligand therapy ([177Lu]Lu-PSMA). Eur Urol Oncol. 2022; In press.

Mottet N, Cornford P, van den Bergh RCN, et al. EAU-EANM-ESTRO-ESUR-ISUP-SIOG guidelines on prostate cancer. Published 2022. https://d56bochluxqnz.cloudfront.net/documents/full-guideline/EAU-EANM-ESTRO-ESUR-ISUP_SIOG-Guidelines-on-Prostate-Cancer-2022.pdf. Accessed 4 Apr 2022.

Fendler WP, Eiber M, Beheshti M, et al. (68)Ga-PSMA PET/CT: joint EANM and SNMMI procedure guideline for prostate cancer imaging: version 1.0. Eur J Nucl Med Mol Imaging. 2017;44(6):1014–24.CrossRef

Gillessen S, Armstrong A, Attard G, et al. Management of patients with advanced prostate cancer: report from the Advanced Prostate Cancer Consensus Conference 2021. Eur Urol. 2022;18:S0302–2838(22) 01807-3.

Fanti S, Goffin K, Hadaschik BA, et al. Consensus statements on PSMA PET/CT response assessment criteria in prostate cancer. Eur J Nucl Med Mol Imaging. 2021;48(2):469–76.CrossRef

Titel: EANM-EAU consensus on PSMA PET/CT in respect to radioligand therapy ([177Lu]Lu-PSMA)
verfasst von: Stefano Fanti
Jolanta Kunikowska
Jochen Walz
Wim Witjes
Anders Bjartell
Publikationsdatum: 14.06.2022
Verlag: Springer Berlin Heidelberg
Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging / Ausgabe 10/2022
Print ISSN: 1619-7070
Elektronische ISSN: 1619-7089
DOI: https://doi.org/10.1007/s00259-022-05864-z

Springer Medizin

Excerpt

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 10/2022

Freely available artificial intelligence for pelvic lymph node metastases in PSMA PET-CT that performs on par with nuclear medicine physicians

Construction and implementation of regional high-level PET alliance based on international consensus

Correction to: An [18F]FDG‑PET/CT deep learning method for fully automated detection of pathological mediastinal lymph nodes in lung cancer patients

Intraoperative MET-receptor targeted fluorescent imaging and spectroscopy for lymph node detection in papillary thyroid cancer: novel diagnostic tools for more selective central lymph node compartment dissection

Response to letter to the editor

Cortical abnormalities of synaptic vesicle protein 2A in focal cortical dysplasia type II identified in vivo with 18F-SynVesT-1 positron emission tomography imaging